Targovax is invited to present at upcoming investor conferences
Oslo, Norway, 21 January 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team will present at upcoming investor conferences.
Date: 22 January 2019
Venue: Redeye Fight Cancer Seminar, Stockholm, Sweden
Presenter: Erik Digman Wiklund (CBO)
Presentation:
- Time: 10:45 CET
Panel discussion:
- The field of Immuno-oncology - how to optimize clinical development - what trends do you see in the market?
- Time: 11:40 CET
The event can be followed live here.
The presentation will be available to download at www.targovax.com after the event.
Date: 7 February 2019
Venue: 5th annual Immuno-oncology (IO) 360°, NYC, USA
Presenter: Erik Digman Wiklund (CBO)
Panel discussion:
- Fundraising in the Current IO Space
- Time: 11:10 AM EST
-------------------------------------------------------------------------------------
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial, with a phase Ib safety lead-in cohort. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS - mutations known to drive cancer. The TG vaccine program has shown a signal of efficacy compared to historical control in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested as monotherapy and will also be tested in combination with KEYTRUDA® (an anti-PD1 check point inhibitor, CPI).